ArticleFrontiers in oncology2025
Immunotherapy combined with chemotherapy: a promising therapeutic approach in the management of colonic squamous cell carcinoma-a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal squamous cell carcinoma (CSCC) is an exceedingly rare malignancy, accounting for approximately 0.41% of all colorectal cancers. This case report describes a 52-year-old male with a history of chronic bronchitis, varicose vein of the lower limb, diabetes, and Hepatitis B cirrhosis, who presented with worsening abdominal pain. The patient underwent a right hemicolectomy, and postoperative pathology revealed a moderately differentiated CSCC with proficient mismatch repair (pMMR) status. The patient was initially treated with the CAPEOX adjuvant chemotherapy regimen, the patient's condition unfortunately progressed. Therefore, the treatment plan has been adjusted to include nab-paclitaxel and carboplatin, in combination with camrelizumab, an Anti-PD-1 therapy, for antitumor therapy. The combination therapy resulted in a partial response. This case highlights the potential efficacy of Anti-PD-1 therapy combined with chemotherapy in CSCC, suggesting a possible treatment approach for this rare cancer subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.